MeiraGTx Announces Positive Clinical Data Demonstrating Treatment with AAV-RPGR Investigational Gene Therapy Improves Vision in X-Linked Retinitis Pigmentosa Patients GlobeNewsWire • 07/17/20
MeiraGTx Holdings PLC (MGTX) Moves to Strong Buy: Rationale Behind the UpgradeZacks Investment Research • 06/26/20
MeiraGTx Announces Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) Designations Granted by the European Medicines Agency to AAV-RPGR Gene Therapy for the Treatment of X-Linked Retinitis PigmentosaGlobeNewsWire • 03/02/20
What Makes MeiraGTx Holdings PLC (MGTX) a Strong Momentum Stock: Buy Now?Zacks Investment Research • 12/24/19